scholarly journals Effect of patiromer on reducing serum potassium and preventing recurrent hyperkalaemia in patients with heart failure and chronic kidney disease on RAAS inhibitors

2015 ◽  
Vol 17 (10) ◽  
pp. 1057-1065 ◽  
Author(s):  
Bertram Pitt ◽  
George L. Bakris ◽  
David A. Bushinsky ◽  
Dahlia Garza ◽  
Martha R. Mayo ◽  
...  
Keyword(s):  
Heart Failure ◽  
Chronic Kidney Disease ◽  
Kidney Disease ◽  
Serum Potassium ◽  
Patients With Heart Failure ◽  
Raas Inhibitors

Practical guidance for the use of potassium binders in the management of hyperkalaemia in patients with heart failure and/or chronic kidney disease

2021 ◽  
pp. 1-11
Author(s):  
Patricia Campbell ◽  
Paul McKeveney ◽  
Kay Donegan ◽  
Charlie Ataliotis ◽  
Carol Patton ◽  
...  
Keyword(s):  
Heart Failure ◽  
Chronic Kidney Disease ◽  
Kidney Disease ◽  
Physiological Role ◽  
Angiotensin Converting Enzyme Inhibitors ◽  
Angiotensin Ii Receptor ◽  
Converting Enzyme Inhibitors ◽  
Patients With Heart Failure ◽  
Raas Inhibitors ◽  
Potassium Binders

Given the critical physiological role of potassium, it is understandable that the development of severe hyperkalaemia requires effective management to reduce its effects, which include muscle weakness, paralysis and cardiac arrhythmias. Hyperkalaemia most often results from the failure of renal adaptation to potassium imbalance. Patients who are most susceptible to the development of hyperkalaemia include those with chronic kidney disease and those with heart failure. These patients are often treated with renin–angiotensin–aldosterone system (RAAS) inhibitors, such as angiotensin-converting enzyme inhibitors and angiotensin II-receptor blockers, but the development of hyperkalaemia can require down-titration or cessation of RAAS inhibitors. This presents a significant challenge to nephrologists, cardiologists and healthcare professionals treating these patients as this can prevent them from receiving maximum guideline-directed RAAS inhibitor therapy. Panellists in this roundtable discussion shared their clinical experiences of using potassium binders to manage hyperkalaemia in patients with chronic kidney disease and patients with heart failure (illustrated with case studies) in Northern Ireland and considered recommendations for the implementation and maintenance of chronic potassium-lowering treatment.

2 Treatment with Patiromer Decreases Aldosterone in Patients with Heart Failure, Chronic Kidney Disease, and Hyperkalemia on RAAS Inhibitors

Heart & Lung ◽  
2017 ◽  
Vol 46 (3) ◽  
pp. 215
Author(s):  
Dahlia Garza ◽  
Coleman Gross ◽  
Martha Mayo ◽  
Jinwei Yuan ◽  
Daniel Wilson ◽  
...  
Keyword(s):  
Heart Failure ◽  
Chronic Kidney Disease ◽  
Kidney Disease ◽  
Patients With Heart Failure ◽  
Raas Inhibitors

scholarly journals Hyperkalaemia in Heart Failure

2021 ◽  
Vol 7 ◽  
Author(s):  
Umar Ismail ◽  
Kiran Sidhu ◽  
Shelley Zieroth
Keyword(s):  
Heart Failure ◽  
Chronic Kidney Disease ◽  
Kidney Disease ◽  
Medical Therapy ◽  
Renin Angiotensin Aldosterone System ◽  
Sodium Zirconium ◽  
Patients With Heart Failure ◽  
Raas Inhibitors ◽  
Potassium Binding ◽  
Sodium Zirconium Cyclosilicate

Hyperkalaemia has become an increasingly prevalent finding in patients with heart failure (HF), especially with renin–angiotensin–aldosterone system (RAAS) inhibitors and angiotensin–neprilysin inhibitors being the cornerstone of medical therapy. Patients living with HF often have other comorbidities, such as diabetes and chronic kidney disease, which predispose to hyperkalaemia. Until now, we have not had any reliable or tolerable therapies for the treatment of hyperkalaemia to facilitate implementation or achievement of target doses of RAAS inhibition. Patiromer sorbitex calcium and sodium zirconium cyclosilicate are two novel potassium-binding resins that have shown promise in the management of patients predisposed to developing recurrent hyperkalaemia, and their use may allow for further optimisation of guideline directed medical therapy.

eGFR Variability in Patients with Heart Failure and Chronic Kidney Disease

2021 ◽  
Author(s):  
Aaron M. Hein ◽  
Julia J. Scialla ◽  
Jie-Lena Sun ◽  
Stephen J. Greene ◽  
Linda K. Shaw ◽  
...  
Keyword(s):  
Heart Failure ◽  
Chronic Kidney Disease ◽  
Kidney Disease ◽  
Patients With Heart Failure

scholarly journals Clinical effect of long-term administration of tolvaptan in patients with heart failure and chronic kidney disease

2018 ◽  
Vol 12 (3) ◽  
pp. 154-160
Author(s):  
Yohei Ono ◽  
Hiroto Takamatsu ◽  
Masahiro Inoue ◽  
Yukio Mabuchi ◽  
Tetsuya Ueda ◽  
...  
Keyword(s):  
Heart Failure ◽  
Chronic Kidney Disease ◽  
Kidney Disease ◽  
Clinical Effect ◽  
Patients With Heart Failure ◽  
Term Administration
Sign in / Sign up

Export Citation Format

Share Document